Overview#
Citizens has reiterated a Market Outperform rating for BeOne Medicines (NASDAQ:ONC), setting a price target of $396.00. Currently, the stock is trading at $323.87, reflecting a notable 40% increase over the past year.
Strong Pipeline and Studies#
The firm emphasized the strength of BeOne's pipeline, particularly following the company's presentation of six studies at the American Association for Cancer Research (AACR) conference. Among these studies is data on the PRMT5 inhibitor BGB-58067, which demonstrated a superior profile in both laboratory and animal studies compared to four competing drugs.
Financial Health#
Citizens highlighted that BeOne Medicines is on track to generate approximately $5 billion in revenue by 2026, bolstered by pending approvals in the U.S. and EU for sonrotoclax. The company boasts a robust cash position of $4.6 billion, with more cash than debt on its balance sheet. Additionally, BeOne maintains an impressive 87% gross profit margin, suggesting strong operational efficiency.
Recent Developments#
In its recent fiscal year 2025 report, BeOne Medicines achieved $5.3 billion in product revenue, aligning with the high end of its guidance. Looking ahead, the company estimates revenue for 2026 to be between $6.2 billion and $6.4 billion. Various analysts have weighed in on the stock, with Wolfe Research initiating coverage with an